HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

REVLON FIRST QUARTER NORTH AMERICA SALES FLAT AT $202.6 MIL.

This article was originally published in The Rose Sheet

Executive Summary

REVLON FIRST QUARTER NORTH AMERICA SALES FLAT AT $202.6 MIL., compared to $201.7 mil. in the first quarter of 1993, the company reported in a recent filing with the Securities and Exchange Commission. Revlon noted that during the quarter, the company's North American business, which includes the U.S. and Canada, benefited from "improved consumer acceptance of new product offerings, an improved dollar share of the core color cosmetics business in the U.S. self-select distribution channel and general improvement in domestic consumer demand in the markets" served by the firm. However, the advances were offset by retailers' "continued" efforts to reduce inventories and the effects of bad weather conditions, Revlon said.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel